An individual participant data network meta-analysis of the APOSTEL trials on the effect of tocolysis in threatened preterm birth between 30–33+6 weeks of gestation in twin pregnancies
Key Points
No clear benefit of nifedipine or atosiban was observed in improving neonatal outcomes in this analysis.
The absence of a notable difference indicates that these treatments may not be effective for twin pregnancies at risk of preterm birth.
Observational analysis of individual participant data from APOSTEL trials provided insights into the efficacy of tocolysis.
These findings may highlight the need for alternative approaches to manage threatened preterm birth in twins.
Abstract
No clear benefit of nifedipine or atosiban over placebo on neonatal outcomes in twin pregnancies with threatened preterm birth between 30+0 and 33+6 weeks was found.
An individual participant data network meta-analysis of the APOSTEL trials on the effect of tocolysis in threatened preterm birth between 30–33+6 weeks of gestation in twin pregnancies | Synapse